Zhejiang University

▲点击图片，了解详情 作者：贝壳社 2025年2月18日，Rokid（灵伴科技）创始人祝铭明和他佩戴自家研发的Rokid Glasses爆火出圈。这款智能眼镜暗藏玄机——发言稿直接存储于眼镜中，手上佩戴的戒指可实现翻页操作。这让众多网友惊叹：“六小龙之后，杭州又一条龙出现了！” 随着杭州多家科技企业的集中爆发，引发了全国性的思考与热议，并抛出诸多疑问：杭州为何能诞生这么多极具潜力的企业？又凭什么让其在全球巨头扎堆的科技领域脱颖而出？ 浙江省政府智库近日发文，细数了成就杭州六小龙的「金木水火土」五字诀——资金扶持、青年人才培育、液态创新网络、接续创新“火种”、厚植创新创业土壤。从中我们也不难窥见，这些企业从初创到腾飞的跃迁，是杭州「雨林式」创新生态的缩影，也向我们揭示了医疗健康产业破局的核心逻辑：唯有借势生态之力，方能化单点突破为系统制胜。 正如贝壳社创始人&董事长姜慧霞女士所说：“企业在成长过程中会面临诸多挑战——从产品选择到投资抉择，再到产品商业化，甚至于创业者的认知边界。正是深谙创业者从0到1的每一步痛点，我们始终坚持做创业者背后的创业者，通过不断整合资源和完善服务，去赋能更多的医健创业企业，真正推动优质项目的商业化落地。” 为此，贝壳社也以「协同创新生态圈」为核心，构建了覆盖「空间-资本-教育-出海-资源」的全周期一站式赋能体系，助力医健创业者破解生存密码，激活增长势能。 协同创新的雨林式双创生态 资本：长期深度陪跑 “杭州七小龙”有一些共同的标签：都处于机器人、人工智能最前沿的科技产业领域，都属于民营小微企业，投入大、周期长、未来收益不确定性高。面对这类“硬核”科技，杭州慷慨解囊，推出“3+N”产业基金，并将扩大到3000亿元规模；研究提出“三个15%”科技投入政策，从制度层面培育耐心资本。这或许正是它们挣脱引力、一飞冲天的首要秘诀。 医健行业同样具有「高投入、长周期、深壁垒」的属性，空有好的创新和技术，若没有持续的资本加持，很容易陷入“创业未半而花光预算”的窘境。 面对这一痛点，贝壳基金自2016年创立之初便确立了独特的价值定位：以资本为纽带，加速科技创新成果转化。我们不仅为全球早期医疗项目提供资金支持，更依托贝壳社深耕多年的产业资源池和专业的孵化及投后能力，通过“投资+服务”驱动模式，深度陪伴企业成长。现已管理医疗健康基金5支，资产规模超5亿元，并投资孵化百普赛斯（301080）、裕策生物、睿丽科技、百凌生物等30余个医健项目。 随着医健产业进入硬科技攻坚深水区，为营造良好的创投生态，构建科创企业与投资机构间的桥梁，2024年贝壳资本应运而生，专注于挖掘高成长潜力的创业项目。为项目提供投融资、战略规划、商业模式优化等全方位支持，帮助其迅速打开市场，推动企业成长。 教育：挖掘培养创新人才 回望这群科技新贵的崛起轨迹，离不开杭州对人才、教育、创业氛围的重视。杭州拥有多所知名高校和科研机构，科研实力雄厚。高校和科研机构与企业之间的紧密合作，为 “七小龙” 的技术创新提供了强大的智力支持。 在医健领域，人才培养的重要性同样不言而喻，医健行业的复杂性与专业性要求创业者不仅要具备深厚的技术背景，还需要敏锐的市场洞察力和创新思维。 而贝壳学社正是以“深度陪伴医健创业者成长”的角色入局，围绕企业发展中的实际问题，通过前一批实战创业先锋成功经验的借鉴和错误失误的避免，自上而下从战略、管理、商业等各个维度击破创业者的困境。 在长周期视角下，持续学习与迭代是创业者在充满不确定性时代中提升成功几率的关键所在。从第一期到第七期，贝壳学社一直陪伴数百位创业者不断求索，帮助他们探索并找到适合自己的进化路径。 资源：全产业链整合与协同 杭州“七小龙”的崛起，不仅是一个现象级的创业故事，更是一个关于资源整合与生态赋能的成功典范。些在短时间内实现爆发式增长，背后正是得益于杭州这座城市在政策、资本、人才、技术等多维度资源的深度加持。从浙江大学等顶尖高校的科研实力，到活跃的创新生态；从活跃的投资机构，到丰富的产业资源，这些要素的协同作用，为企业快速成长提供了强劲动力。 海纳百川，润泽万物。在医健行业迎来“命运共同体”时代的今天，资源整合与协同创新的重要性更加凸显。贝壳社经过10余年的发展，深度链接政府、科研院所、临床机构、投资机构、第三方服务商、CXO等产业高端资源，构建起一个覆盖全球的生命健康人才项目引进、转化孵化和产业化等全产业链的协同创新生态。 出海：加速国际化布局 回溯历史，杭州在别人犹豫时迈步，在别人彷徨时加速，一次次点燃、接续创新火种，让“星星之火”汇聚成“燎原烈焰”。 贝壳社作为医健创新创业领域的开拓者，始终以前瞻性的眼光布局全球市场。早在2016年，我们就在墨尔本创立了贝壳社澳洲创新中心。通过全方位链接澳洲政府、行业协会、科研机构、临床医院及CRO等生态资源，贝壳社为国内医健企业提供了一站式的临床管理服务和快捷的澳洲准入资质获取通道。 我们不仅直接触达政策端、科研端、临床端、资本端、渠道端等产业链上下游全景，更致力于为创业者搭建起一座通向国际市场的桥梁，助其在全球化的浪潮中把握机遇，点燃新增长引擎，开启全球化燎原之路。 空间：多元创业孵化载体 “七小龙”在杭州的成长成功，离不开足够肥沃的创新土壤、链珠成串的创新创业载体以及将政策势能、市场动能与人文基因熔铸为支撑科技创新的“有机质”和“富集层”。 在当前全球医健产业蓬勃发展的浪潮中，产业园区作为医健产业发展的重要载体和依托，以独特的优势成为推动优质企业落地、积聚专业人才、提升产业竞争优势等的关键力量。 作为专注于生命健康领域的专业产业园区，青蓝港湾致力于打造更懂医健创业者的产业社区，精心构建从研发孵化到产业化的完整产业生态链条，提供配套的海外技术创新中心、开放性CXO创新服务平台、医学成果转化平台、澳洲临床试验的一站式产业服务平台等。 截至目前，青蓝港湾在长三角地区所运营产业园面积已达300000平方米，累计孵化企业超400家。作为杭州创业创新的标杆，青蓝港湾凭借全链条服务能级和精准的创新孵化模式，所运营的中澳生物医药产业科技园由杭州高新区（滨江）与科技部火炬中心联合共建，致力于构建海内外高能级创新平台，并成功获评“市级优秀五星孵化器”，是高新区（滨江）生物医药产业发展的战略高地；而作为G60科创大走廊重要一级，天目医药港医药产业孵化园被评为“杭州市生物医药特色产业园区”，正发展成为十四五规划中重要产业平台。 写在最后：生态雨林，协同赋能 独角兽不是偶然，而是生态的必然。从杭州“七小龙”的爆火出圈不难发现，协同式创新生态不仅是一种发展理念，更是一套被实践验证的成功方法论。 贝壳社将以全链式创新生态之力重构产业规则，做医健创业的「生态雨林」——资本注入发展动能、思维迭代生生不息、资源驱动精准赋能、出海探索增长引擎、空间孕育无限可能。 让我们共同期待，见证更多改变世界的医健创新力量破土而出！ 关于贝壳社 贝壳社是国内领先的医健创新创业服务平台，为医健创业者提供全路径创业服务。通过产业空间运营、创业教育、投资孵化、数字化赋能、企业价值增长等服务体系，给医健创业企业提供产业空间、人才战略培养、投融资、产业生态资源、数字化转型等服务。同时，贝壳社布局澳洲，帮助国内生物医药企业加速走向海外；成立“泰格-泰珑-贝壳社企业经营服务中心”为企业成长提供全生命周期的增值服务，提高企业运营效率，加快企业成长发展。我们深度链接政府、科研院所、临床机构、投资机构、第三方服务商、CXO等行业资源，致力于赋能医疗健康创业公司成长，推动创新技术造福人类生命健康。 往 期 推 荐 1 杭州“六小龙”出圈背后：医药创业的“杭州模式”如何炼成？ 2 批准！200亿中药龙头将并入华润医药帝国 _ 3 寒冬逆袭，创新药领域的潜力黑马 _ *声明：本文仅用于分享，不构成任何投资建议，且非治疗方案推荐。 投稿请添加小助手：bioclub666

FRIDAY, Feb. 14, 2025 -- Women with epilepsy may have offspring with decreased bone metabolism and lower birth weight, according to a study published online Feb. 3 in the Annals of Clinical and Translational Neurology . Huali Luo, from Zhejiang University in China, and colleagues retrospectively analyzed data from 83 parturients with epilepsy receiving antenatal care (2012 through 2021) and a control group of 249 parturients without epilepsy. The researchers found that women with epilepsy were significantly more likely to undergo a cesarean section with a lower abortion rate (55.4 versus 37.3 percent). Offspring femoral length in women with epilepsy was significantly reduced versus the control group (6.812 versus 6.923 cm) when adjusting for potential confounding variables. Compared with offspring whose mothers used a single antiseizure medication (ASM) or none, those born to mothers using multiple ASMs had significantly reduced femoral and biparietal lengths. Additionally, using multiple ASMs was associated with significantly lower birth weight in offspring versus women not using ASMs. "The application of a single ASM during pregnancy is the optimal choice for pregnant women with epilepsy and their offspring, as it can not only control the seizures to reduce the harm caused by seizures during pregnancy but also minimize the restriction of ASMs on the growth and development of offspring," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

BEIJING, Dec. 13, 2024 /PRNewswire/ -- Mango, a tropical fruit rich in nutrients, has a vital position in Myanmar's agriculture. Myanmar researcher Nann Miky Moh Moh worked with Chinese scientists at Zhejiang University in east China on genetically improving the flavor and variety of the fruit. Continue Reading Myanmar researcher Nann Miky Moh Moh is working in a lab. (Courtesy photo) Although the regulatory roles of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) have been widely studied in many plants, mango research in this field remained unexplored. "This is the first study to provide information on non-coding RNAs (ncRNAs) of mango," Moh Moh told Science and Technology Daily. During her time at Zhejiang University, she worked with Professor Chen Ming's bioinformatics research group at the College of Life Sciences. Their research aimed to identify the genetic factors affecting mango flavor and heat resistance. "For mango flavor development, some major genes play a role in its resistance mechanisms," Chen said. "We studied the processes related to temperature regulation and identified the specific genes or targets involved." Using advanced computational tools and through experiments, Moh Moh identified over 100 miRNAs and more than 60 cold-responsive lncRNAs interact with key gene family in Mango. These discoveries have provided new insights into genetic mechanisms that could inform breeding strategies for improving mango varieties. "The results of our research could potentially be integrated with local institutions to transform genetic findings into improved mango cultivars," Chen said. A journey of discovery For Moh Moh, conducting research in China has been a transformative experience. Driven by a deep interest in biological systems, she initially pursued biotechnology, later switching to bioinformatics due to its potential to analyze large datasets using advanced computational tools. "As Myanmar researchers, we often have ideas but lack the facilities to pursue them fully," Moh Moh explained. In contrast, China's cutting-edge research infrastructure and collaborative opportunities attracted her. She joined Zhejiang University through a program funded by the Ministry of Science and Technology of China, working with a high-level research team. "Zhejiang University is one of China's leading institutions, highly regarded globally. Its strong reputation in life sciences made it my top choice," she said. Her dedication did not go unnoticed by her team. "She's serious and devoted to research," Chen said. Before arriving in China, Moh Moh had conducted molecular analysis on mangoes but lacked expertise in computational analysis using advanced bioinformatics tools. At Zhejiang University, she started learning advanced bioinformatics techniques and tools from scratch and worked closely with her team to bridge the knowledge gap. "Whenever I think about my time at Zhejiang University, I feel happy," she said. "The lab members were kind, talented and hardworking. They inspired me both professionally and personally." Strengthening Myanmar-China collaboration Currently working in a private company in Thailand, Moh Moh remembers her time at Zhejiang University fondly and hopes to return to China for further research. "Living and working in China broadened my understanding of Chinese culture, history and philosophy," she said. China has significantly increased investments in research, development and renewable energy, fostering international collaborations. Myanmar and China share a long-standing "pauk-phaw" (fraternal) friendship, which will celebrate its 75th anniversary in 2025. In recent years, the two nations have deepened cooperation in science, technology and innovation. In December 2023, China's Ministry of Commerce and the Mekong River nations, including Myanmar, adopted the Five-Year Development Plan for Cross-Border Economic Cooperation (2023 — 2027). The plan includes a framework for collaboration in science, technology and innovation across the Mekong-Lancang region. In November 2023, China and Myanmar signed a memorandum of understanding to enhance cooperative technology and innovation initiatives. A future rooted in science China also plans to implement the Lancang-Mekong Space Cooperation Plan, which includes launching the "Fudan-1 Lancang-Mekong Future Star" project and establishing the Lancang-Mekong youth astronomical science research center. These initiatives will strengthen scientific collaboration and innovation in the region. As China and Myanmar continue to identify priorities for joint research, the success of projects like Moh Moh's mango study highlights the transformative power of international cooperation. By leveraging advanced technology and fostering cross-border partnerships, Myanmar's mango industry — and its broader agricultural sector — could see significant advancements in the years to come. This article is written in cooperation with the China Science and Technology Exchange Center (CSTEC). SOURCE Science and Technology Daily WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED